TCGA-A7-A13D-01B-04R-A277-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 32
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.270
- MITOTIC_SPINDLE+0.220
- UV_RESPONSE_DN+0.130
- WNT_BETA_CATENIN_SIGNALING+0.120
- PANCREAS_BETA_CELLS+0.090
- HEDGEHOG_SIGNALING+0.050
- G2M_CHECKPOINT+0.040
- KRAS_SIGNALING_DN+0.040
- TGF_BETA_SIGNALING+0.030
- NOTCH_SIGNALING-0.050
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.620
- ESTROGEN_RESPONSE_LATE-0.510
- DNA_REPAIR-0.490
- ESTROGEN_RESPONSE_EARLY-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- FATTY_ACID_METABOLISM-0.480
- ADIPOGENESIS-0.470
- P53_PATHWAY-0.450
- APOPTOSIS-0.420
- CHOLESTEROL_HOMEOSTASIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.940 |
| 2 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.933 |
| 3 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.931 |
| 4 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.923 |
| 5 | e356598b-7611-492a-98ed-ef2ec1b77b7a | — | — | 0.919 |
| 6 | ed8896f8-24ef-43a4-ace6-ed9353bd11c2 | — | — | 0.908 |
| 7 | SRR627462 | GTEX | — | 0.903 |
| 8 | SRR627429 | GTEX | — | 0.902 |
| 9 | MNG790 | — | — | 0.901 |
| 10 | AUR-AERW-TTP1-B-1-0-R-A741-41 | — | D | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |